Helicobacter Pylori Infections Pipeline Insight

DelveInsight’s, “Helicobacter Pylori Infections – Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Helicobacter Pylori Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Helicobacter Pylori Infections Understanding

Helicobacter Pylori Infections: Overview

Helicobacter pylori (H. pylori) is a gram-negative, microaerophilic, spiral-shaped and flagellated bacterium infecting about half the world’s population whose main reservoir is the human stomach. H. pylori possesses microbiological characteristics that allow it to survive in extremely adverse conditions such as the gastric acidic environment. H. pylori infection is the main cause of chronic gastritis and peptic ulcer disease. H. pylori has a determinant pathogenic role in the development of distal gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma; in fact, it can contribute to gastric carcinogenesis by stimulating gastric cell proliferation without counterbalancing with adequate apoptosis.

Symptoms

The symptoms of Helicobacter Pylori Infections include:

  • Anemia
  • Gastrointestinal bleeding
  • Weight loss
  • Frequent burping
  • Bloating

Diagnosis

H. pylori infection can be diagnosed by noninvasive methods or by endoscopic biopsy of the gastric mucosa; the selection of the appropriate test depends on the clinical setting. Noninvasive methods include the urea breath test, serologic tests, and stool antigen assays. The urea breath test relies on the abundant, H. pylori–derived urease activity in the stomach; it qualitatively detects active infection with a sensitivity and specificity of more than 90 percent. The test is indicated for the initial diagnosis of the infection and for follow-up of eradication therapy.

Treatment

Antibiotics are combined with proton-pump inhibitors or ranitidine bismuth citrate and so-called triple therapies, combinations of one antisecretory agent with two antimicrobial agents for 7 to 14 days, have been extensively evaluated, and several regimens have been approved by the Food and Drug Administration (FDA). The combination of two or more antimicrobial agents increases rates of cure and reduces the risk of selecting for resistant H. pylori. The chief antimicrobial agents used in these regimens are amoxicillin, clarithromycin, metronidazole, tetracycline, and bismuth.

Gastroparesis Emerging Drugs

  • TAK-438: Takeda

TAK-438 is an experimental drug that is a potassium- competitive acid blocker and is being studied in Phase III of clinical study. Originally, this compound was developed by Takeda and now licensed by Otsuka Pharmaceuticals and Phantom Pharmaceuticals.


  • Tegoprazan: Pfizer

CJ-12420 is a Phase 3 potassium- competitive acid blocker and H (+) and K (+) - exchanging ATPase inhibitors. It was originally developed by Pfizer but it is now licensed by HK inno.N, RaQualia Pharma, Shandong Luoxin Pharmaceutical.

Further product details are provided in the report……..

Helicobacter Pylori Infections: Therapeutic Assessment

This segment of the report provides insights about the different Helicobacter Pylori Infections drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Helicobacter Pylori Infections There are approx. 10+ key companies which are developing the therapies for Helicobacter Pylori Infections. The companies which have their Helicobacter Pylori Infections drug candidates in the most advanced stage, i.e. phase III include, Takeda.
  • Phases


DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Helicobacter Pylori Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.


Helicobacter Pylori Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Helicobacter Pylori Infections therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Helicobacter Pylori Infections drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Helicobacter Pylori Infections R&D. The therapies under development are focused on novel approaches to treat/improve Helicobacter Pylori Infections.
  • In April 2020, Meridian Bioscience, Inc. a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.


Helicobacter Pylori Infections Report Insights

  • Helicobacter Pylori Infections Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs


Helicobacter Pylori Infections Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Helicobacter Pylori Infections drugs?
  • How many Helicobacter Pylori Infections drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Helicobacter Pylori Infections?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Helicobacter Pylori Infections therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Helicobacter Pylori Infections and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Takeda
  • Pfizer
  • Servatus Biopharmaceuticals

Key Products

  • TAK-408
  • Tegoprazan
  • SVT-1C469

 

Introduction

Executive Summary

Helicobacter Pylori Infections: Overview

• Causes

• Mechanism of Action

• Signs and Symptoms

• Diagnosis

• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type

• Assessment by Stage and Product Type

• Assessment by Route of Administration

• Assessment by Stage and Route of Administration

• Assessment by Molecule Type

• Assessment by Stage and Molecule Type

Helicobacter Pylori Infections – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Helicobacter Pylori Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Helicobacter Pylori Infections Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis

• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

TAK-438: Takeda

• Product Description

• Research and Development

• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Metopimazine: Neurogastrx

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

SVT-1C469: Servatus Biopharmaceuticals

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

RQ 00201894: RaQualia Pharma

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Helicobacter Pylori Infections Key Companies

Helicobacter Pylori Infections Key Products

Helicobacter Pylori Infections - Unmet Needs

Helicobacter Pylori Infections - Market Drivers and Barriers

Helicobacter Pylori Infections - Future Perspectives and Conclusion

Helicobacter Pylori Infections Analyst Views

Helicobacter Pylori Infections Key Companies

Appendix

List of Table

 Table 1 Total Products for Helicobacter Pylori Infections

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List of Figures

 Figure 1 Total Products for Helicobacter Pylori Infections

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

• Takeda

• Pfizer

• Servatus Biopharmaceuticals

  • Tags:
  • Helicobacter Pylori Infections Pipe...
  • Helicobacter Pylori Infections clin...
  • Helicobacter Pylori Infections comp...
  • Helicobacter Pylori Infections drug...
  • Helicobacter Pylori Infections ther...
  • Helicobacter Pylori Infections trea...
  • Helicobacter Pylori Infections pipe...
  • Helicobacter Pylori Infections pipe...

Forward to Friend

Need A Quote